Pomdoctor holds extraordinary shareholder meeting on ADR program termination proposal
POM•Pomdoctor shareholders endorsed a non-binding proposal to terminate the ADR program and directly list Class A shares on Nasdaq; they also approved a 10-for-1 share consolidation, but implementation of both plans was not confirmed.
1. Shareholders approve resolutions
At an extraordinary meeting on Sept. 30, 2026, Pomdoctor shareholders backed a non-binding advisory resolution endorsing termination of the ADR program and a direct Nasdaq listing of Class A shares. They also adopted an ordinary resolution authorizing a 10-for-1 share consolidation. The proposed ADR termination, direct listing and consolidation are planned to take effect on the same date, but execution was not confirmed.
